Alere Inc (ALR)

50.18
0.05 0.10
NYSE : Health Care
Prev Close 50.23
Open 50.20
Day Low/High 50.14 / 50.25
52 Wk Low/High 31.47 / 50.30
Volume 1.52M
Avg Volume 2.14M
Exchange NYSE
Shares Outstanding 87.37M
Market Cap 4.38B
EPS -1.80
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Abbott Is on Track to Meet Integration Objectives

In turn, this will increase the company's profit margins.

Weekly Roundup

After a busy Thursday, markets look forward to economic data and the Fed meeting next week. In the portfolio, we dropped a tech stock and added a healthcare name.

Xilinx, Alere, Xerox, Huntsman: 'Mad Money' Lightning Round

Xilinx, Alere, Xerox, Huntsman: 'Mad Money' Lightning Round

Jim Cramer likes Xilinx and Abbott Labs, but he's bearish on Xerox and Huntsman.

Thursday's 'Triathlon of Terror' Is Overblown: Cramer's 'Mad Money' Recap (Wednesday 6/7/17)

Thursday's 'Triathlon of Terror' Is Overblown: Cramer's 'Mad Money' Recap (Wednesday 6/7/17)

Comey's testimony? U.K. elections? Eurozone news? These can be new buying opportunities, says Jim Cramer.

Greenlight Capital Quadrupled General Motors Stake in Activist Push

Greenlight Capital Quadrupled General Motors Stake in Activist Push

David Einhorn is going all-in on General Motors.

Alere Launches The Alere™ Malaria Ag P.f, The First-Ever Rapid Test To Screen Malaria Infection In Asymptomatic Individuals

New test provides powerful tool to help meet malaria eradication goals

Abbott CEO Upbeat Despite Ongoing Merger Headaches

Abbott CEO Upbeat Despite Ongoing Merger Headaches

Troubles at a plant acquired with St. Jude and continuing risks to closing the Alere deal linger over M&A spree.

Merger Challenges, FDA Concerns Dampen Abbott Gains Despite Strong First Quarter

Merger Challenges, FDA Concerns Dampen Abbott Gains Despite Strong First Quarter

Sales grew 29.7% in a year marked by acquisitions and new products, while comparable operations sales grew 3.2%.

Alere Stock Surging on Latest Abbott Agreement

Alere Stock Surging on Latest Abbott Agreement

Abbott will now pay a lower price to acquire Alere.

Can Abbott Outperform Despite Alere?

Can Abbott Outperform Despite Alere?

Abbott Laboratories appears poised to enjoy a fruitful year, though its litigation with former takeover target Alere could hold it back.

Abbott Laboratories Stock Downgraded by BMO

Abbott Laboratories Stock Downgraded by BMO

Abbott Laboratories downgraded to 'market perform.'

Alere Provides Update On Arriva Medical

Alere Receives FDA CLIA Waiver For Alere™ I RSV Rapid Molecular Test

First molecular test to detect RSV infection in 13 minutes or less now widely available in a broad range of healthcare settings

Abbott Shares Dip on Mixed Fourth-Quarter Earnings

Abbott Shares Dip on Mixed Fourth-Quarter Earnings

Abbott Labs' shares fell nearly 1% in premarket trading after the company reported mixed earnings results.